ezetimibe/atorvastatin olainfarm 10 mg/80 mg apvalkotās tabletes
olainfarm, as, latvia - ezetimibum, atorvastatinum - apvalkotā tablete - 10 mg/80 mg
ezetimibe/atorvastatin 10 mg/10 mg apvalkotās tabletes
stada arzneimittel ag, germany - ezetimibum, atorvastatinum - apvalkotā tablete - 10 mg/10 mg
ezetimibe/atorvastatin stada 10 mg/20 mg apvalkotās tabletes
stada arzneimittel ag, germany - ezetimibum, atorvastatinum - apvalkotā tablete - 10 mg/20 mg
ezetimibe/atorvastatin stada 10 mg/40 mg apvalkotās tabletes
stada arzneimittel ag, germany - ezetimibum, atorvastatinum - apvalkotā tablete - 10 mg/40 mg
ezetimibe/atorvastatin stada 10 mg/80 mg apvalkotās tabletes
stada arzneimittel ag, germany - ezetimibum, atorvastatinum - apvalkotā tablete - 10 mg/80 mg
azithromycin teva 250 mg disperģējamās tabletes
teva pharma b.v., netherlands - azitromicīns - disperģējamā tablete - 250 mg
azithromycin teva 500 mg disperģējamās tabletes
teva pharma b.v., netherlands - azitromicīns - disperģējamā tablete - 500 mg
zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.
isoptin retard 120 mg ilgstošās darbības tabletes
viatris sia, latvia - verapamila hidrohlorīds - ilgstošās darbības tablete - 120 mg
isoptin retard 240 mg ilgstošās darbības tabletes
viatris sia, latvia - verapamila hidrohlorīds - ilgstošās darbības tablete - 240 mg